Welcome to our dedicated page for Cuprina Holdings (Cayman) news (Ticker: CUPR), a resource for investors and traders seeking the latest updates and insights on Cuprina Holdings (Cayman) stock.
Cuprina Holdings (Cayman) Limited reports developments tied to its biomedical product portfolio for chronic wounds, infertility, medical waste recycling and cosmeceuticals. Company updates focus on MEDIFLY, its medical-grade maggot debridement therapy for chronic wound management, including regulatory classification and regional commercialization steps.
Recurring news also covers product and technology diversification, including IVF media production capabilities in Singapore, iodine-based wound care collaborations, and exclusive licensing rights for high-temperature steam treatment technology used to sterilize, decontaminate and recycle plastic-based medical waste. Cuprina's announcements also include scientific advisory activity, public-company communications, financial results and Nasdaq listing-compliance matters.
Cuprina Holdings (Nasdaq: CUPR) announced it regained compliance with Nasdaq Capital Market listing requirements as of June 11, 2026. The company previously faced a Staff Delisting Determination for failing the $1.00 minimum bid price rule, but now meets the Minimum Bid Requirement and avoids a scheduled July 7, 2026 hearing.
Cuprina Holdings (Nasdaq:CUPR) has completed a reverse stock split effective May 27, 2026 and requested a hearing before the Nasdaq Hearings Panel to maintain its Nasdaq Capital Market listing.
The move follows a Nasdaq determination to delist after CUPR failed the $1.00 minimum bid price requirement by May 26, 2026. The hearing request keeps trading and listing active pending the Panel’s decision, and the company expects the share consolidation to help restore bid-price compliance.
Cuprina Holdings (Nasdaq:CUPR) will implement a 1-for-8 share consolidation of its Class A and Class B ordinary shares, effective on or around May 27, 2026. Post-consolidation, Class A shares will continue trading on Nasdaq under symbol CUPR with new CUSIP G2592E110.
The action aims to help Cuprina regain compliance with Nasdaq Rule 5550(a)(2) and maintain its listing. Every 8 shares at par value US$0.001 will convert into 1 share at par value US$0.008, with fractional shares rounded up. Board approval occurred on April 21, 2026 and shareholder approval on May 14, 2026.
Cuprina (Nasdaq:CUPR) announced a regulatory milestone and advisory board expansion on March 11, 2026. Cuprina’s 49% associate, Cuprina MENA, received SFDA product classification for MEDIFLY as a Medical Device–Drug combination, enabling finalization of Saudi technical requirements for commercial distribution.
The company also appointed Dr. Enming Yong to its Medical & Scientific Advisory Board to provide clinical oversight, protocol review, and endocrinology expertise. Cuprina reported regional clinical engagement activities in Hong Kong and Singapore and held its inaugural advisory board meeting on March 2, 2026.
Cuprina Holdings (Nasdaq: CUPR) reported results for the six months ended June 30, 2025, showing revenue of $18,040 (down 40% YoY) and a net loss of $1,528,121 (or $(.08) per share).
The company completed an IVF media production facility with ISO 13485 certification, secured an FDA-approved license for medical maggots in the U.S., advanced a MENA maggot-manufacturing lab, licensed UNIDO/GEF medical-waste recycling technology for Southeast Asia, and signed joint ventures for iodine-based antiseptics.
Cash was $3.22M at June 30, 2025; Cuprina projects 2026 revenue of $1.0–$1.5M and plans multiple commercial rollouts and human clinical trials.
Cuprina Holdings (Nasdaq: CUPR) received a Nasdaq noncompliance notice dated November 26, 2025 for failing to meet the $1.00 minimum bid under Nasdaq Listing Rule 5550(a)(2).
Cuprina has an initial 180-calendar-day compliance period to regain the $1.00 closing bid for at least ten consecutive business days. If not regained, the company may be eligible for a second 180-day period by meeting market value and other initial listing standards (excluding the bid price) and providing written notice to cure, potentially by effecting a reverse stock split. Shares will continue to trade uninterrupted under the symbol CUPR while the process unfolds. Cuprina is evaluating options to regain compliance but stated there is no assurance it will do so.
Cuprina (Nasdaq: CUPR) signed a joint venture with Singapore-based Aiodine Laboratory to develop, test and commercialize Aiodine's novel iodine-based disinfectant for antiseptic wound care, disinfectants and daily home-use antiseptics, with additional applications under evaluation including personal care, oral hygiene and veterinary uses.
The JV assigns global sales, marketing and distribution to Cuprina and proprietary iodine technology to Aiodine. Clinical studies to pursue regulatory approvals are planned to commence in 2026. A peer-reviewed case series (March 26, 2025) reported wound improvement in three of four patients within two weeks without toxicity. Market references: wound care ≈ US$21B (2024) to US$36B (2032); antiseptics estimate ≈ US$48M (2027).
Cuprina (Nasdaq: CUPR) signed a Memorandum of Understanding on October 27, 2025 with Singapore Biowaste Solutions (SBS) to explore integrating Cuprina’s medical waste recycling technology into SBS’s Singapore facility.
The collaboration covers a feasibility study and pilot using Cuprina’s exclusive Southeast Asia license to a high-temperature autoclaving process that sterilizes and converts plastic medical waste into resins. Cuprina will provide technical expertise and training; SBS will provide operational data, facility access, and regulatory support. The partners will seek revenue-sharing models and regional expansion, and Cuprina expects regulatory approvals and operations could begin by end of 2026.
Cuprina (NASDAQ:CUPR) announced that management, including CEO David Quek, will present live and answer questions at the Skyline Signature Series™ on Wednesday, October 8, 2025 at 11:00 AM ET. The event is an interactive online presentation that allows investors to ask questions in real time. Interested individual and institutional investors, advisors, and analysts must pre-register to attend.
Registration is required via the event sign-up link and the presentation is scheduled as a live webcast format for investor engagement.
Cuprina Holdings (Nasdaq: CUPR) has secured exclusive licensing rights to Southeast Asia's first UNIDO/GEF-demonstrated medical waste recycling technology. The technology, licensed from Zhejiang Heliang Technology, uses advanced high-temperature steam treatment to sterilize and recycle medical waste into high-value resins, particularly focusing on plastic-based materials.
The license covers Singapore with expansion options to 10 additional Southeast Asian countries. The technology offers an environmentally friendly alternative to traditional incineration methods, supported by extensive regulatory approvals and ISO certifications (9001, 14001, 45001). Singapore's biohazardous medical waste increased from 4,400 tons in 2016 to 5,700 tons in 2020, growing approximately 5% annually.
The global medical waste management market is projected to grow from $34.06 billion in 2023 to $59.42 billion by 2030, with Asia-Pacific as the fastest-growing region.